Trials / Terminated
TerminatedNCT06830681
CMPA-GO Study: Growth and Safety Outcomes in Infants With CMPA Fed a Novel Extensively Hydrolyzed Formula
A Growth, Tolerability, and Safety Study of a Novel Extensively Hydrolyzed Formula (eHF) in Infants With Cow's Milk Protein Allergy (CMPA)
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Société des Produits Nestlé (SPN) · Industry
- Sex
- All
- Age
- 4 Weeks – 22 Weeks
- Healthy volunteers
- Not accepted
Summary
CMPA-GO Study: Growth and safety Outcomes in infants with CMPA fed a novel extensively hydrolyzed formula
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | New generation eHF | New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA. |
| DIETARY_SUPPLEMENT | Commercial eHF | Commercial whey-based eHF formula intended for the dietary management of infants with CMPA. |
Timeline
- Start date
- 2025-01-07
- Primary completion
- 2025-05-23
- Completion
- 2025-06-23
- First posted
- 2025-02-17
- Last updated
- 2025-06-29
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT06830681. Inclusion in this directory is not an endorsement.